News
The cyclodextrin field in motion
Developments at Cholrem and across the field that Cholrem helped open.
Three-vessel coronary case report submitted for peer review
Cholrem has submitted a case report to a cardiology journal documenting severe three-vessel coronary disease, bypass declined, reduced to patent arteries on CT after eleven months of nightly HPβCD therapy with no other treatment. Publication details will be posted here.
See the images →FDA approves Lembaz™, the first cyclodextrin medicine
Beren Therapeutics’ HPβCD product was approved by the US FDA for Niemann-Pick disease type C, the first FDA licence for the molecule, granted for intrathecal use. Beren raised US$300 million earlier in 2026.
FDA clears cyclodextrin trial in coronary artery disease
Cyclarity Therapeutics received FDA clearance to begin a Phase 1b study of an engineered cyclodextrin in patients with coronary artery disease, with CT coronary angiography before and after dosing. Its Phase 1 ran at Monash University’s Victorian Heart Institute in Australia. The FDA has now cleared a coronary study of the class, using the same imaging Cholrem has worked with for years.
Intravenous HPβCD drug application filed
Rafael Holdings submitted a New Drug Application for intravenous HPβCD in Niemann-Pick disease type C, adding to the systemic human safety record for the molecule.
Coronary calcification regression published
Cholrem’s multi-centre longitudinal analysis reports serial, scanner-matched coronary calcium scores falling on the high-viscosity formulation, a result no drug class has produced in a controlled trial.
Read the paper →Synthesis paper in preparation
A synthesis of Cholrem’s seven papers lays each finding against the predictions already in the independent literature. Nine of twelve were predicted before Cholrem observed them in humans.